Compass Pathways Plc (CMPS) - Net Assets
Based on the latest financial reports, Compass Pathways Plc (CMPS) has net assets worth $-52.85 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($210.35 Million) and total liabilities ($263.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CMPS tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-52.85 Million |
| % of Total Assets | -25.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | -118.58% |
| 10-Year Change | N/A |
| Growth Volatility | 834.55 |
Compass Pathways Plc - Net Assets Trend (2018–2025)
This chart illustrates how Compass Pathways Plc's net assets have evolved over time, based on quarterly financial data. See Compass Pathways Plc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Compass Pathways Plc (2018–2025)
The table below shows the annual net assets of Compass Pathways Plc from 2018 to 2025. For live valuation and market cap data, see Compass Pathways Plc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-52.85 Million | -134.16% |
| 2024-12-31 | $154.69 Million | -31.47% |
| 2023-12-31 | $225.74 Million | +24.53% |
| 2022-12-31 | $181.28 Million | -36.26% |
| 2021-12-31 | $284.41 Million | +44.69% |
| 2020-12-31 | $196.56 Million | +2207.60% |
| 2019-12-31 | $8.52 Million | +159.28% |
| 2018-12-31 | $-14.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Compass Pathways Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 80464100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $973.00K | % |
| Other Comprehensive Income | $-14.79 Million | % |
| Other Components | $783.56 Million | % |
| Total Equity | $-52.85 Million | 100.00% |
Compass Pathways Plc Competitors by Market Cap
The table below lists competitors of Compass Pathways Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Derichebourg
PA:DBG
|
$1.34 Billion |
|
Sally Beauty Holdings Inc
NYSE:SBH
|
$1.34 Billion |
|
Cofco Biochemical Anhui Co Ltd
SHE:000930
|
$1.34 Billion |
|
HannStar Board Corp
TW:5469
|
$1.34 Billion |
|
Zhejiang Huangma Technology Co Ltd
SHG:603181
|
$1.34 Billion |
|
Dogan Sirketler Grubu Holding AS
IS:DOHOL
|
$1.34 Billion |
|
Paymentus Holdings, Inc.
NYSE:PAY
|
$1.34 Billion |
|
Wuxi Zhenhua Auto Parts Co. Ltd.
SHG:605319
|
$1.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Compass Pathways Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 154,695,000 to -52,848,000, a change of -207,543,000 (-134.2%).
- Net loss of 287,862,000 reduced equity.
- New share issuances of 140,357,000 increased equity.
- Other comprehensive income increased equity by 1,405,000.
- Other factors decreased equity by 61,443,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-287.86 Million | -544.7% |
| Share Issuances | $140.36 Million | +265.59% |
| Other Comprehensive Income | $1.41 Million | +2.66% |
| Other Changes | $-61.44 Million | -116.26% |
| Total Change | $- | -134.16% |
Book Value vs Market Value Analysis
This analysis compares Compass Pathways Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-2.56 | $11.79 | x |
| 2019-12-31 | $0.39 | $11.79 | x |
| 2020-12-31 | $5.47 | $11.79 | x |
| 2021-12-31 | $7.11 | $11.79 | x |
| 2022-12-31 | $4.27 | $11.79 | x |
| 2023-12-31 | $4.42 | $11.79 | x |
| 2024-12-31 | $2.29 | $11.79 | x |
| 2025-12-31 | $-0.57 | $11.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Compass Pathways Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-61.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.78 Million |
| 2019 | -230.24% | 0.00% | 0.00x | 3.80x | $-20.46 Million |
| 2020 | -30.93% | 0.00% | 0.00x | 1.04x | $-80.46 Million |
| 2021 | -25.22% | 0.00% | 0.00x | 1.06x | $-100.18 Million |
| 2022 | -50.48% | 0.00% | 0.00x | 1.09x | $-109.63 Million |
| 2023 | -52.48% | 0.00% | 0.00x | 1.22x | $-141.04 Million |
| 2024 | -100.28% | 0.00% | 0.00x | 1.38x | $-170.59 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-282.58 Million |
Industry Comparison
This section compares Compass Pathways Plc's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $330,251,300
- Average return on equity (ROE) among peers: -5.69%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Compass Pathways Plc (CMPS) | $-52.85 Million | 0.00% | N/A | $1.34 Billion |
| Acadia Healthcare Company Inc (ACHC) | $432.55 Million | 4.72% | 1.27x | $1.52 Billion |
| Addus HomeCare Corporation (ADUS) | $34.58 Million | 11.64% | 2.93x | $1.69 Billion |
| agilon health Inc (AGL) | $470.95 Million | -55.24% | 2.68x | $264.44 Million |
| Airsculpt Technologies Inc (AIRS) | $79.29 Million | -10.41% | 1.65x | $358.37 Million |
| Amedisys Inc (AMED) | $454.23 Million | -18.40% | 0.61x | $3.32 Billion |
| AMN Healthcare Services Inc (AMN) | $217.74 Million | 15.12% | 1.72x | $624.22 Million |
| American Shared Hospital Service (AMS) | $-22.30 Million | 0.00% | 0.00x | $8.87 Million |
| American Oncology Network Inc. (AONC) | $108.01 Million | -3.68% | 3.35x | $292.48 Million |
| Ardent Health Partners, Inc. (ARDT) | $1.08 Billion | 4.65% | 3.71x | $1.35 Billion |
| Astrana Health Inc (ASTH) | $445.15 Million | -5.34% | 0.84x | $1.90 Billion |
About Compass Pathways Plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly … Read more